Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH) : Real-World Evidence from the Combined OPUS/OrPHeUS Dataset
© 2024. The Author(s)..
INTRODUCTION: Data on real-world clinical practice and outcomes of patients with pulmonary arterial hypertension associated with connective tissue disease (CTD-PAH) are scarce. The OPUS/OrPHeUS studies enrolled patients newly initiating macitentan, including those with CTD-PAH. This analysis describes patient characteristics, treatment patterns, outcomes, and safety profiles of patients with CTD-PAH newly initiating macitentan in the US using the OPUS/OrPHeUS combined dataset.
METHODS: OPUS was a prospective, US, multicenter, long-term, observational drug registry (April 2014-June 2020). OrPHeUS was a retrospective, US, multicenter medical chart review (October 2013-March 2017). The characteristics, treatment patterns, safety, and outcomes during macitentan treatment of patients with CTD-PAH and its subgroups systemic sclerosis (SSc-PAH), systemic lupus erythematosus (SLE-PAH), and mixed CTD (MCTD-PAH) were descriptively compared to patients with idiopathic/heritable PAH (I/HPAH).
RESULTS: The combined OPUS/OrPHeUS population included 2498 patients with I/HPAH and 1192 patients with CTD-PAH (708 SSc-PAH; 159 SLE-PAH; 124 MCTD-PAH, and 201 other CTD-PAH etiologies). At macitentan initiation for patients with I/HPAH and CTD-PAH, respectively: 61.2 and 69.3% were in World Health Organization functional class (WHO FC) III/IV; median 6-min walk distance was 289 and 279 m; and 58.1 and 65.2% received macitentan as combination therapy. During follow-up, for patients with I/HPAH and CTD-PAH, respectively: median duration of macitentan exposure observed was 14.0 and 15.8 months; 79.0 and 83.0% experienced an adverse event; Kaplan-Meier estimates (95% confidence limits [CL]) of patients free from all-cause hospitalization at 1 year were 60.3% (58.1, 62.4) and 59.3% (56.1, 62.3); and Kaplan-Meier estimates (95% CL) of survival at 1 year were 90.5% (89.1, 91.7) and 90.6% (88.6, 92.3).
CONCLUSIONS: Macitentan was used in clinical practice in patients with CTD-PAH and its subgroups, including as combination therapy. The safety and tolerability profile of macitentan in patients with CTD-PAH was comparable to that of patients with I/HPAH.
TRIAL REGISTRATION: OPsumit® Users Registry (OPUS): NCT02126943; Opsumit® Historical Users cohort (OrPHeUS): NCT03197688; www.
CLINICALTRIALS: gov Graphical abstract available for this article.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Cardiology and therapy - (2024) vom: 07. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Channick, Richard [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Connective tissue disease |
|---|
| Anmerkungen: |
Date Revised 07.03.2024 published: Print-Electronic ClinicalTrials.gov: NCT02126943, NCT03197688 Citation Status Publisher |
|---|
| doi: |
10.1007/s40119-024-00361-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36941182X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36941182X | ||
| 003 | DE-627 | ||
| 005 | 20240307233239.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240307s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40119-024-00361-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1319.xml |
| 035 | |a (DE-627)NLM36941182X | ||
| 035 | |a (NLM)38451426 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Channick, Richard |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH) |b Real-World Evidence from the Combined OPUS/OrPHeUS Dataset |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 07.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT02126943, NCT03197688 | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a INTRODUCTION: Data on real-world clinical practice and outcomes of patients with pulmonary arterial hypertension associated with connective tissue disease (CTD-PAH) are scarce. The OPUS/OrPHeUS studies enrolled patients newly initiating macitentan, including those with CTD-PAH. This analysis describes patient characteristics, treatment patterns, outcomes, and safety profiles of patients with CTD-PAH newly initiating macitentan in the US using the OPUS/OrPHeUS combined dataset | ||
| 520 | |a METHODS: OPUS was a prospective, US, multicenter, long-term, observational drug registry (April 2014-June 2020). OrPHeUS was a retrospective, US, multicenter medical chart review (October 2013-March 2017). The characteristics, treatment patterns, safety, and outcomes during macitentan treatment of patients with CTD-PAH and its subgroups systemic sclerosis (SSc-PAH), systemic lupus erythematosus (SLE-PAH), and mixed CTD (MCTD-PAH) were descriptively compared to patients with idiopathic/heritable PAH (I/HPAH) | ||
| 520 | |a RESULTS: The combined OPUS/OrPHeUS population included 2498 patients with I/HPAH and 1192 patients with CTD-PAH (708 SSc-PAH; 159 SLE-PAH; 124 MCTD-PAH, and 201 other CTD-PAH etiologies). At macitentan initiation for patients with I/HPAH and CTD-PAH, respectively: 61.2 and 69.3% were in World Health Organization functional class (WHO FC) III/IV; median 6-min walk distance was 289 and 279 m; and 58.1 and 65.2% received macitentan as combination therapy. During follow-up, for patients with I/HPAH and CTD-PAH, respectively: median duration of macitentan exposure observed was 14.0 and 15.8 months; 79.0 and 83.0% experienced an adverse event; Kaplan-Meier estimates (95% confidence limits [CL]) of patients free from all-cause hospitalization at 1 year were 60.3% (58.1, 62.4) and 59.3% (56.1, 62.3); and Kaplan-Meier estimates (95% CL) of survival at 1 year were 90.5% (89.1, 91.7) and 90.6% (88.6, 92.3) | ||
| 520 | |a CONCLUSIONS: Macitentan was used in clinical practice in patients with CTD-PAH and its subgroups, including as combination therapy. The safety and tolerability profile of macitentan in patients with CTD-PAH was comparable to that of patients with I/HPAH | ||
| 520 | |a TRIAL REGISTRATION: OPsumit® Users Registry (OPUS): NCT02126943; Opsumit® Historical Users cohort (OrPHeUS): NCT03197688; www | ||
| 520 | |a CLINICALTRIALS: gov Graphical abstract available for this article | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Connective tissue disease | |
| 650 | 4 | |a Macitentan | |
| 650 | 4 | |a Mixed connective tissue disease | |
| 650 | 4 | |a Pulmonary arterial hypertension | |
| 650 | 4 | |a Real-world evidence | |
| 650 | 4 | |a Scleroderma | |
| 650 | 4 | |a Systemic lupus erythematosus | |
| 650 | 4 | |a Systemic sclerosis | |
| 700 | 1 | |a Chin, Kelly M |e verfasserin |4 aut | |
| 700 | 1 | |a McLaughlin, Vallerie V |e verfasserin |4 aut | |
| 700 | 1 | |a Lammi, Matthew R |e verfasserin |4 aut | |
| 700 | 1 | |a Zamanian, Roham T |e verfasserin |4 aut | |
| 700 | 1 | |a Turricchia, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Ong, Rose |e verfasserin |4 aut | |
| 700 | 1 | |a Mitchell, Lada |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Nick H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiology and therapy |d 2012 |g (2024) vom: 07. März |w (DE-627)NLM241091462 |x 2193-8261 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:07 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s40119-024-00361-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 07 |c 03 | ||